Condition: Sepsis · Coagulopathy · Sponsor: Bayer
Researchers are looking for a better way to treat people who have sepsis induced coagulopathy. Sepsis happens when bacteria and their toxins spread in the blood, causing an infection. To overcome the infection the body responds activating the immune system, sometimes this immune response is too active and causes uncontrolled blood clot formation, also called sepsis-induced coagulopathy. Sepsis coagulopathy damages blood vessels and organs and leads to low platelet levels in the body. In severe cases, it can even lead to death. The main purpose of this first in patient study is to learn about how safe BAY 3389934 is, its suitable dose, and how it affects the participants with sepsis induced coagulopathy. For this study, researchers will enroll people receiving treatment for sepsis induced coagulopathy in a hospital intensive care unit (ICU). For this, the researchers will collect the number of participants with medical problems during and after receiving BAY 3389934. These medical problems are also known as "adverse events". Doctors keep track of all medical problems that happen in studies, even if they do not think they might be related to the study treatments. Participants will be divided into 2 groups. The first group will receive the lowest starting dose of BAY3389934. The researcher will carefully monitor how the participant responds to the medication and may adjust the dose, either increasing or decreasing it based on the safety and the tolerability of the drug. If n…
This description comes directly from the study's public registry record.
Bayer Clinical Trials Contact · (+)1-888-84 22937 · clinical-trials-contact@bayer.com
Always discuss trial participation with your own doctor first.
| UZ Antwerpen - Intensive Care | Edegem, Belgium | Not Yet Recruiting |
| Centre Hospitalier Universitaire (CHU) de Liege - Domaine Universitaire du Sart Tilman - Intensive Care | Liège, Belgium | Not Yet Recruiting |
| Clinique Saint-Pierre d'Ottignies - Intensive Care | Ottignies-Louvain-la-Neuve, Belgium | Recruiting |
| Universite Catholique de Louvain (UCL) - Cliniques Universitaires Saint-Luc - Intensive Care | Woluwe-Saint-Lambert, Belgium | Not Yet Recruiting |
| CHRU de Tours - Hôpital Bretonneau - Médecine Intensive Réanimation | Tours, Centre-Val de Loire, France | Not Yet Recruiting |
| Hopitaux Universitaires de Strasbourg Nouvel Hopital Civil - Service de Médecine Intensive Réanimation | Strasbourg, Grand Est, France | Recruiting |
| Centre Hospitalier Universitaire de Limoges Dupuytren 1 - Service de réanimation polyvalente | Limoges, New Aquitaine, France | Recruiting |
| Centre Hospitalier Universitaire d'Angers - Médecine Intensive Réanimation et Médecine Hyperbare | Angers, Pays de la Loire Region, France | Not Yet Recruiting |
| Centre Hospitalier Départemental Vendée - Service de réanimation polyvalente | La Roche-sur-Yon, Pays de la Loire Region, France | Not Yet Recruiting |
| Hopital Hotel Dieu Nantes - Service de Médecine Intensive Réanimation | Nantes, Pays de la Loire Region, France | Not Yet Recruiting |
| Hôpital Raymond-Poincaré - Service de Médecine Intensive - Réanimation, Médecine Hyperbare | Garches, Île-de-France Region, France | Not Yet Recruiting |
| Klinikum der Universität München AöR - Klinik für Anaesthesiologie (Campus Großhadern) | München, Bavaria, Germany | Not Yet Recruiting |
+ 8 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06854640